Clinitech Laboratory Limited to Review H1 FY27 Results Nov 13

Clinitech Laboratory will consider unaudited standalone and consolidated results for the half year ended September 30, 2026, at a board meeting on November 13, 2026, following FY26 revenue from operations growth of 15% to ₹9.48 crore. The meeting is scheduled for 12:00 noon IST through video conferencing and will also review the internal audit report.

Why is Clinitech Laboratory holding a board meeting on November 13?

Clinitech Laboratory is holding the meeting to consider and approve its unaudited standalone and consolidated financial results, along with the Limited Review Report, for H1 FY27 ended September 30, 2026. The company informed BSE of the scheduled meeting on November 6, 2026.

The timing follows the end of the September half-year reporting period. The company has not yet disclosed the H1 FY27 financial outcome in the information provided. Therefore, the November 13 board meeting is an approval and disclosure event, rather than an announcement of confirmed new earnings figures.

The meeting will be conducted via video conferencing at 12:00 noon IST. Clinitech Laboratory has also stated that the board will review the internal audit report for the relevant period. This places both financial reporting and internal control review on the board's agenda.

What will the board consider at the H1 FY27 results meeting?

The board will consider unaudited standalone and consolidated H1 FY27 financial results and the associated Limited Review Report. A limited review is the review process attached to interim financial statements, while the company’s annual accounts are subject to a statutory audit.

The agenda also includes the internal audit report. No further details on its observations, if any, were disclosed in the information provided. Investors will need to wait for the meeting outcome and the financial results filing for the underlying operating and financial details.

Clinitech Laboratory had closed its trading window for insiders from October 1, 2026, ahead of the financial-results consideration. The company said the window would reopen 48 hours after the results are declared, in line with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

How did Clinitech Laboratory perform in FY26?

Clinitech Laboratory reported FY26 revenue from operations of ₹9.48 crore, up 15% from ₹8.23 crore in FY25. Total income rose to ₹9.66 crore from ₹8.46 crore, while total expenses increased to ₹9.06 crore from ₹7.91 crore.

Standalone net profit for FY26 was ₹0.42 crore, a 7% increase from ₹0.39 crore in the previous year. Basic earnings per share stood at ₹1.85, compared with ₹1.90 in FY25. The company’s statutory auditors, Kale Malde & Co., issued an unmodified opinion on the standalone and consolidated financial statements.

On a consolidated basis, revenue from operations was ₹9.49 crore in FY26, compared with ₹8.23 crore a year earlier. Consolidated profit attributable to owners of the parent was ₹0.42 crore, against ₹0.39 crore in FY25. For the half year ended March 31, 2026, the company reported profit after tax of ₹0.12 crore.

What does the H1 FY27 announcement mean for investors?

The H1 FY27 filing will provide the next reported measure of whether Clinitech Laboratory has maintained revenue growth after FY26. Its earlier H1 FY26 results showed revenue from operations of ₹5.08 crore, up 24.64% year on year from ₹4.08 crore, while profit after tax was ₹0.21 crore.

The company had also reported that it used ₹4.28 crore from IPO proceeds of ₹5.78 crore, leaving ₹1.50 crore for diagnostic-business expansion. The H1 FY27 results may provide updated financial context on operations, although no fresh update on the remaining IPO proceeds has been disclosed in the current board-meeting intimation.

For shareholders, the immediate focus is the eventual results release, the Limited Review Report and any observations disclosed with the board outcome. The current announcement does not provide a share-price movement, earnings guidance, dividend proposal or operating forecast. It only confirms the date and matters proposed for board consideration.

Conclusion

Clinitech Laboratory’s November 13 meeting is the scheduled forum for approving H1 FY27 unaudited standalone and consolidated results and reviewing its internal audit report. The announcement follows a FY26 in which revenue from operations rose 15% to ₹9.48 crore and standalone net profit reached ₹0.42 crore.

Investors should watch for the board-meeting outcome, the H1 FY27 financial statements and the Limited Review Report after the meeting. The trading window is set to reopen 48 hours after the results declaration, while the company has not disclosed any other scheduled financial or operational update in the current notice.